Medifast, Inc.
MED · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $602,463 | $1,072,054 | $1,598,577 | $1,526,087 |
| % Growth | -43.8% | -32.9% | 4.8% | – |
| Cost of Goods Sold | $157,840 | $296,204 | $458,163 | $398,490 |
| Gross Profit | $444,623 | $775,850 | $1,140,414 | $1,127,597 |
| % Margin | 73.8% | 72.4% | 71.3% | 73.9% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $441,745 | $649,448 | $955,608 | $911,356 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $441,745 | $649,448 | $955,608 | $911,356 |
| Operating Income | $2,878 | $126,402 | $184,806 | $216,241 |
| % Margin | 0.5% | 11.8% | 11.6% | 14.2% |
| Other Income/Exp. Net | $909 | $2,395 | -$747 | -$112 |
| Pre-Tax Income | $3,787 | $128,797 | $184,059 | $216,129 |
| Tax Expense | $1,696 | $29,382 | $40,491 | $52,098 |
| Net Income | $2,091 | $99,415 | $143,568 | $164,031 |
| % Margin | 0.3% | 9.3% | 9% | 10.7% |
| EPS | 0.19 | 9.1 | 12.82 | 14.01 |
| % Growth | -97.9% | -29% | -8.5% | – |
| EPS Diluted | 0.19 | 9.1 | 12.73 | 13.89 |
| Weighted Avg Shares Out | 10,930 | 10,884 | 11,195 | 11,705 |
| Weighted Avg Shares Out Dil | 10,963 | 10,921 | 11,276 | 11,813 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,804 | $2,490 | $0 | $0 |
| Interest Expense | $0 | $0 | $701 | $0 |
| Depreciation & Amortization | $12,707 | $13,107 | $10,980 | $6,812 |
| EBITDA | $15,585 | $139,509 | $195,740 | $223,053 |
| % Margin | 2.6% | 13% | 12.2% | 14.6% |